Carfilzomib Improves The Efficacy Of Multiple Myeloma Treatment

Carfilzomib improves the efficacy of multiple myeloma treatment

Although the survival rate of multiple myeloma (MM) has been greatly improved, but the recurrence of the disease is still more common, it also needs more for its new treatment.

Phase 3 clinical trials have shown that lenalidomide combined with high-dose dexamethasone has a better effect than single-dose dexamethasone in patients with recurrent MM, with a median progression-free survival of 11.1 months after treatment and a total response Rate of up to 60%, the program has been approved for patients with recurrent MM.

Studies have shown that the use of a small dose of dexamethasone a greater dose of dexamethasone has a better efficacy and less toxicity for newly diagnosed MM patients. A recent phase 3 clinical trial showed that for patients with newly diagnosed MM, lenalidomide was given weekly dexamethasone treatment, and progression-free survival was significantly improved.

Carfilzomib is an epoxy ketone proteasome inhibitor that is selective and irreversibly bound to a structural proteasome and an immunoprotegerase. Studies have shown that the total response rate for carbofuran is 23.7% for patients with recurrent and refractory MM, and is therefore approved by the United States for such patients.

Phase 1 and 2 clinical trials have shown that carbofazide, lenalidomide combined with weekly dexamethasone treatment, is effective for recurrent MM and its side effects are consistent with the side effects of various drugs.

Professor Stewart conducted a randomized, noninvasive, multicenter Phase 3 clinical trial for comparing patients with recurrent MM, Carfilzomib, lenalidomide combined with dexamethasone and lenalidomide in combination with dexamethasone Program safety and efficacy of differences, interim analysis results published in the latest issue of the "New England Journal of Medicine" on.

A total of 792 patients with recurrent MM were enrolled in this study. All patients had blood and liver and kidney function levels (creatinine clearance> 50 ml / min). Patients with grade III and above heart failure, or those with grade 3 and above or more than two weeks of peripheral neuropathy (or grade 2 pain) were excluded.

The overall survival rate was 73.3% vs 65.0% in the Carfilzomib group and the control group, respectively, and the total response rate (partial response or improvement) in the Carfilzomib group was 87.1% %, 66.7%.

The incidence of adverse events in the Carfilzomib group and the control group was 83.7% and 80.7%, respectively, and 15.3% and 17.7% of the patients in the two groups were discontinued due to adverse events. The Carfilzomib group had higher health Related quality of life.

Thus, the use of Carfilzomib in combination with lenalidomide and dexamethasone in patients with recurrent MM can significantly improve progression-free survival and have a better risk / benefit ratio.

At present, there are studies to explore the optimal dose and treatment of Carfilzomib, I believe that with the further study, Carfilzomib can be better and more convenient for MM patients.